Search Result

Results for "

Ischaemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Adenosine Kinase (1) Adrenergic Receptor (2) Akt (1) Apoptosis (1) Calcium Channel (1) Caspase (1) Cyclophilin (1) Dynamin (2) Endogenous Metabolite (5) GlyT (1) iGluR (4) Isotope-Labeled Compounds (1) NF-κB (1) Potassium Channel (6) Sigma Receptor (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (11) Endocrinology (1) Inflammation/Immunology (4) Metabolic Disease (8) Neurological Disease (10)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101101

L-701252	iGluR	Neurological Disease
L-701252 is a potent antagonist of glycine site NMDA receptor with an IC₅₀ of 420 nM. L-701252 provides a small degree of neuroprotection in global cerebral ischaemia .

HY-113147A

L-Palmitoylcarnitine chloride 1 Publications Verification	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-113147

L-Palmitoylcarnitine 1 Publications Verification	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-113147B

L-Palmitoylcarnitine TFA 1 Publications Verification	Endogenous Metabolite Potassium Channel	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-148327

AK-IN-1	Adenosine Kinase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
AK-IN-1 (compound 4072-2732) is an adenosine kinase (AK) inhibitor that is competitive for adenosine (Ado) but not for ATP. AK-IN-1 inhibits 86%, 87% and 89% of AK activity at concentrations of 2, 4 and 10 µM, respectively. AK-IN-1 has good potential for research in many disease areas, including ischaemia, inflammation and seizures .

HY-W018026

Oxfenicine L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842	Others	Metabolic Disease
Oxfenicine (L-p-Hydroxyphenylglycine) is an orally active carnitine palmitoyltransferase-1 inhibitor. Oxfenicine inhibits the oxidation of fatty acid in heart. Oxfenicine protects heart from necrotic tissue damage during ischaemia .

HY-131041

Ned-K	Calcium Channel	Cardiovascular Disease
Ned-K is a nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist. Ned-K is effective at dampening simulated ischaemia and reperfusion (sIR)-induced Ca ²⁺ oscillations in cardiomyocytes .

HY-N6634

Araloside C	Others	Others
Araloside C exhibits protective effects against myocardial ischaemia/reperfusion injury .

HY-155941

5-Hydroxydecanoic acid	Potassium Channel	Neurological Disease
5-Hydroxydecanoic acid (5-HD） is a K_ATP channel antagonist，which has the effect of blocking the K K_ATP channel only during ischaemia by competing with the ATP binding site and does not affect pancreatic K_ATP channels .

HY-106039

LY 215490	iGluR	Neurological Disease
LY 215490 is a selective, competitive AMPA receptor antagonist against AMPA, CGSl9755 and kainate with IC₅₀ values of 4.8, 26.4 and 247 μM, respectively. LY 215490 shows neuroprotective effects in focal ischaemia .

HY-117699

Fluanisone	Others	Neurological Disease
Fluanisone has potent sedative effect in vivo. Fluanisone can be used to study schizophrenia .

HY-15068

NBQX Maximum Cited Publications 10 Publications Verification FG9202	iGluR	Neurological Disease
NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity .

HY-15068A

NBQX disodium Maximum Cited Publications 10 Publications Verification FG9202 disodium	iGluR	Neurological Disease
NBQX disodium (FG9202 disodium) is a highly selective and competitive AMPA receptor antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .

HY-117699R

Fluanisone (Standard)	Others	Neurological Disease
Fluanisone (Standard) is the analytical standard of Fluanisone. This product is intended for research and analytical applications. Fluanisone has potent sedative effect in vivo. Fluanisone can be used to study schizophrenia .

HY-131370B

Intralipid 20%	Others	Cancer
Intralipid 20% is a safe fat emulsion that can be used as a nutritional supplement. Intralipid 20% effectively inhibits the opening of the mitochondrial permeability transition pore, effectively protecting the heart from ischaemia-reperfusion injury and has some potential to modulate the innate immune response .

HY-107526

(Rac)-ALX 5407 (Rac)-NFPS	GlyT	Neurological Disease
NFPS is a selective, non-competitive glycine transporter-1 (GlyT1) inhibitor with IC₅₀s of 2.8 nM and 9.8 nM for hGlyT1 and rGlyT1, respectively . NFPS exerts neuroprotection via glyR alpha1 subunit in the rat model of transient focal cerebral ischaemia and reperfusion .

HY-113147AS

L-Palmitoylcarnitine-d3 hydrochloride	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine-d₃ (hydrochloride) is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].

HY-113147S1

L-Palmitoylcarnitine-d9	Isotope-Labeled Compounds Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine-d₉ is deuterium labeled L-Palmitoylcarnitine. L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-108515

(+)-Igmesine hydrochloride JO1784	Sigma Receptor	Neurological Disease
(+)-Igmesine hydrochloride (JO1784) is an orally active and selective σ receptor ligand with neuroprotective and anti-amnesic activities .

HY-107571

VULM 1457	Acyltransferase	Cardiovascular Disease Metabolic Disease
VULM 1457 is a potent inhibitor of cholesterol acyltransferase (acyl-CoA). VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM 1457 has the potential for the research of diabetes mellitus and hypercholesterolaemia .

HY-121012

(rac)-AG-205	NF-κB Akt	Endocrinology
(rac)-AG-205 is a potent inhibitor of progesterone receptor membrane component 1 (Pgrmc1) that induces genes involved in sterol synthesis, including the INSIG1 protein, which forms a complex with PGRMC1. (rac)-AG-205 prevents neuronal resistance to hypoxic ischaemia by blocking NF-kB signalling and activation of the BDNF/PI3K/AKT pathway .

HY-157088

C105SR	Caspase Apoptosis Cyclophilin	Others
C105SR is a cyclophilin D (CypD) inhibitor targeting to peptidyl-prolylcis-trans isomerase (PPIase). C105SR inhibits mitochondrial permeability transition opening (mPTP) with an IC ₅₀ of 5 nM. C105SR inhibits hypoxia and reoxygenation inudced hepatocyte apoptosis and increases the level of calcium retention capacity (CRC). C105SR exhibits hepaprotective effect in ischaemia-reperfusion injury (IRI) mouse model .

HY-101337

Imiloxan RS 21361 free base	Adrenergic Receptor	Metabolic Disease Inflammation/Immunology
Imiloxan is a potent and selective alpha 2B-adrenoceptor antagonist. Imiloxan has the potential for acute kidney injury research .

HY-152086

DRP1i27	Dynamin	Cardiovascular Disease
DRP1i27 is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury .

HY-152086A

DRP1i27 dihydrochloride	Dynamin	Cardiovascular Disease
DRP1i27 dihydrochloride is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 dihydrochloride binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 dihydrochloride targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury .

HY-121166

Levobetaxolol (S)-Betaxolol	Adrenergic Receptor	Others
Levobetaxolol is a potent and high affinity β-adrenergic antagonist with IC₅₀ values of 33.2, 2970, 709 nM for guinea pig atrial β1, tracheal β2 and rat colonic β3 receptors, respectively. Levobetaxolol reduces IOP (intraocular pressure). Levobetaxolol exhibits a micromolar affinity for L-type Ca21-channels. Levobetaxolol decreases the effects of ischaemia/reperfusion injury in rats. Levobetaxolol has the potential for the research of glaucoma .

Cat. No.	Product Name	Target	Research Area

HY-P3211A

Nangibotide TFA 3 Publications Verification LR12 TFA	Peptides	Cardiovascular Disease Inflammation/Immunology
Nangibotide TFA is a TREM-1 receptor inhibitor that can modulate innate immune response. Nangibotide TFA can reduce systemic and in situ inflammatory reaction in rodent models of myocardial ischaemia-reperfusion .

HY-P3211

Nangibotide LR12	Peptides	Inflammation/Immunology
Nangibotide is a TREM-1 receptor inhibitor that can modulate innate immune response. Nangibotide can reduce systemic and in situ inflammatory reaction in rodent models of myocardial ischaemia‐reperfusion .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113147A

L-Palmitoylcarnitine chloride 1 Publications Verification	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Potassium Channel Endogenous Metabolite
L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-113147

L-Palmitoylcarnitine 1 Publications Verification	Cardiovascular Disease Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Potassium Channel Endogenous Metabolite
L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-113147B

L-Palmitoylcarnitine TFA 1 Publications Verification	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Potassium Channel
L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-N6634

Araloside C	Triterpenes Classification of Application Fields Terpenoids Source classification Other Diseases Aralia elata (Miq.) Seem. Plants Disease Research Fields Araliaceae	Others
Araloside C exhibits protective effects against myocardial ischaemia/reperfusion injury .

Cat. No.	Product Name	Chemical Structure

HY-113147AS

L-Palmitoylcarnitine-d3 hydrochloride
L-Palmitoylcarnitine-d₃ (hydrochloride) is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].

L-Palmitoylcarnitine-d3 hydrochloride

L-Palmitoylcarnitine-d₃ (hydrochloride) is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].

HY-113147S1

L-Palmitoylcarnitine-d9
L-Palmitoylcarnitine-d₉ is deuterium labeled L-Palmitoylcarnitine. L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks